A-Sales

Amigo AI

63 Qualified Meetings in 8 Weeks for Amigo AI

Amigo AI builds and trains patient-facing clinical AI agents: intake, triage, care navigation, 24/7 patient support, work that would otherwise sit with a care team that does not have the hours. What separates Amigo from the rest of the healthcare AI field is where they put the effort. Most clinical AI companies build the agent and then work out how to make it safe. Amigo built the training process first: their agents complete what the company calls a digital residency, running through millions of simulated clinical scenarios and adversarial edge cases before they are allowed near a live patient. The name is deliberate: it is modelled on how doctors are actually trained. In March 2026 Amigo raised an $11m Series A led by Madrona with participation from Optum Ventures, bringing total funding to $17m.

40+Providers at every account booked
63Qualified sales meetings in 8 weeks
7+Meetings per week, sustained

The Challenge

The hardest sale in healthcare

Most healthcare software can fail quietly. A scheduling tool that drops an appointment creates an annoyance. A monitoring platform that misses an alert creates an incident report. An AI agent that talks to patients does not have that luxury: the failure mode is a patient receiving bad guidance, and everyone in the buying committee knows it. Every clinical leader Amigo speaks to has already imagined the worst version of this product before the call begins.

That inverts the usual outbound problem. In most categories the job is to create interest. Here interest already exists, because every health system in the world is short-staffed and knows it. The job is to clear a safety objection fast enough that a conversation can happen at all.

The buyer is not at a desk

The people who decide whether an AI agent speaks to their patients are clinical and operational leadership: medical directors, chief medical officers, heads of operations, practice and clinic leadership. These people are on wards, in clinic, and in meetings. They are not working through an inbox. Cold email into clinical leadership underperforms for a structural reason that no amount of copywriting fixes: the channel does not match the working day.

A narrow, non-negotiable profile

Amigo's product economics work at scale. A clinic with six providers does not have the patient volume to justify the deployment. The target was healthcare organisations with 40 or more providers, and that floor was not a guideline. A size floor that specific cannot be met with a database export: provider counts are not a standard field, they are frequently wrong where they exist at all, and a healthcare list filtered on employee headcount returns the wrong organisations entirely, because a hospital's staff count and its provider count are very different numbers.

Post-raise pressure

Amigo closed its Series A in March 2026. A-Sales launched in June. A funding round resets what a go-to-market team is measured on: before it, the job is proving the product works; after it, the job is proving the market is bigger than the customers you already have, on a timeline the board can see. Building an in-house SDR function to do that would have taken most of the following year.

In most categories outbound has to create interest. Here interest already existed. The job was to clear the safety objection fast enough for a conversation to happen.

The Approach

Lead with safety, not with benefit

This is the decision the whole account turns on, and it runs against every instinct in outbound. The standard opener names the pain and offers relief: your care team is stretched, our agents handle intake and triage, can we talk. On this product that opener fails, because the prospect is not thinking about their stretched care team. They are thinking about an AI giving a patient the wrong answer.

So A-Sales opened on the objection instead. Amigo agents complete a digital residency across millions of simulated clinical scenarios before they touch a live case. That single fact does more work in the first fifteen seconds than any benefit statement, because it answers the question the prospect was already forming. Naming the risk before the prospect does is disarming. It signals that the person calling understands what they are asking a clinical leader to consider.

The phone, because clinical leaders answer it

Clinical leadership is reachable by voice and largely unreachable by cold email. That is a fact about how the job works, not a preference about channels. A medical director between clinics will take a call; the same person will not read a cold email that arrives during a ward round and is buried by the afternoon. The phone also suits a product where the safety question has to be handled live. A rep can hear the hesitation, address it, and keep the conversation going.

The list was built to the provider floor, by hand

Every account was researched against the 40-provider threshold individually, rather than filtered from a general healthcare export. This is slow, and on this ICP it is the only method that works. Provider count is not a reliable database field, and filtering a healthcare list on employee headcount produces a list of the wrong organisations. A hospital with 3,000 employees and a clinic group with 3,000 employees are not remotely the same target. Building to the real criterion meant every dial was on profile, which on a floor this specific is the difference between a working programme and a wasted quarter.

Live from launch week

No infrastructure build, no warmup period, no setup phase billed as progress. Lists built, script written, calling from the launch week. Cold email could not have done this: sending domains need two to three weeks of warmup before any cold volume goes out, so an email-led programme would have spent the first three weeks producing nothing. Calling has no warmup requirement.

The standard opener names the pain and offers relief. On this product it fails, because the prospect is not thinking about their stretched team. They are thinking about what happens when the agent is wrong.

The Process

Week 1: build and launch

  • Account universe defined at 40 or more providers, with no exceptions
  • Every account researched against the provider floor by hand
  • Clinical and operational leadership mapped by name and role
  • Qualification standard agreed in writing with Amigo
  • Calling live in the launch week

Weeks 1 to 8: run and tighten

  • Safety evidence built into the opening of every call
  • Script rebuilt weekly against live objection data
  • Objection library built from real recorded calls
  • Every meeting reviewed by Amigo, with feedback fed straight back into targeting

Ongoing

  • Continuous list expansion against the provider floor
  • Callback list worked daily
  • Weekly reporting on booked, held and rejected meetings

How We Define a Qualified Meeting

A meeting only counts when it meets criteria agreed with the client before calling starts. Right organisation profile, right seniority, genuine interest, confirmed slot, and a prospect who knows who they are meeting and why.

On this account the profile criterion was the strict one. An organisation below 40 providers was not a qualified meeting no matter how interested the person on the phone was.

If a meeting does not meet the standard, it does not get billed. Amigo can reject a meeting, and rejections are reviewed rather than argued about. A-Sales earns the overwhelming majority of its revenue from the per qualified sales meeting fee, so a meeting the client cannot use is a loss on both sides.

Results

Current as of eight weeks into a live, ongoing engagement.

  • 63 qualified sales meetings booked in 8 weeks
  • All with hospitals and clinics of 40 or more providers
  • More than 7 meetings booked per week, sustained
  • Live and booking from launch week
  • Engagement ongoing

Individual prospect accounts stay unnamed, because that is Amigo's pipeline. Meetings were booked with clinical and operational leadership at hospitals and multi-site clinic groups, every one of them at organisations of 40 or more providers.

What Made the Difference

Open on the objection, not the benefit

When the barrier is trust rather than interest, the fastest route into a conversation is to answer the fear before the prospect voices it. Naming the risk first is disarming. Waiting for the prospect to raise it means the call is already over.

The client's own proof is the best opener available

Amigo had done the hard work already with the digital residency. The job was not to invent a message, it was to recognise which existing fact did the most work in the first fifteen seconds and put it at the front.

Match the channel to the buyer's working day

Clinical leaders are not at desks. That is not a copywriting problem, it is a channel problem, and no subject line fixes it.

A hard profile floor has to be built, not filtered

Provider count is not a reliable database field. Meeting a criterion that specific means researching to it directly. Slow, and the only method that produces a usable list.

Speed after a raise comes from the channel choice

Being live in launch week is not effort, it is picking the one channel with no warmup requirement.

Keep reading

More campaigns

Different brief, same process behind the phone.

Want a write-up with your name on it?

Tell us who you sell to. We'll tell you how many meetings we can book, and what it costs.

  • Pay-per-appointment available
  • First meetings in 2–4 weeks
  • We say no if the fit is wrong